FDA Clearance Tracker · P150031-S049
Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System
Last checked: Nov 20, 2026Latest source record: Oct 27, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Oct 27, 2022
Approved
Time to decision
205 days
Received Apr 5, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150031-S049
- Device name
- Vercise Genus DBS System, Vercise Gevia DBS System, Vercise PC DBS System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Apr 5, 2022
- Decided
- Oct 27, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the addition of the 2x8 Contact Lead Extensions.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.